多靶点粪便DNA检测用于结肠癌筛查的不当开单情况
本研究回顾了500例接受多靶点粪便DNA(mt-sDNA)检测患者的病历,依据USPSTF标准评估开单适当性。结果显示22.2%的检测开单不当,最常见原因为10年内曾行结肠镜检查。不当检测率随种族和开单医生专科显著变化,内科医生开单最多。
要点
- 22.2%的mt-sDNA检测开单不当,最常见原因是10年内曾行结肠镜检查。
- 不当检测率随种族和开单医生专科显著变化,内科医生开单最多。
- 不当检测率不随性别或保险类型显著变化。
核心结论
- 约22.2%的mt-sDNA检测开单不当,提示医生可能不熟悉指南适应症,导致不当转诊和费用增加。
研究设计与样本
- 回顾性病历审查研究,共7,345例患者接受mt-sDNA检测,随机抽取前500例病历,依据USPSTF标准评估开单适当性,排除7例有超过一次不当开单者。
主要发现
- 500例中22.2%的mt-sDNA检测开单不当。
- 不当开单最常见原因是10年内曾行结肠镜检查。
- 不当检测率随种族和开单医生专科显著变化,内科医生开单最多。
- 不当检测率不随性别或保险类型显著变化。
关键数值与推荐
- CRC筛查推荐45-75岁成人;mt-sDNA适用于45-85岁无症状个体,不适用于直肠出血、缺铁性贫血、腺瘤性息肉、10年内曾行结肠镜检查、CRC家族史、过去6个月内CRC筛查检测阳性、年龄小于45岁或大于85岁者。
临床怎么用
- 全科医生开单mt-sDNA前应核对适应症,尤其注意10年内结肠镜检查史等禁忌情况。
- 对CRC风险增加的患者,应考虑更敏感的结肠镜检查而非mt-sDNA。
局限性
- 仅审查了前500例病历,可能不代表全部7,345例。
- 未通过医生调查或访谈了解不当开单的动机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: CRC screening is recommended for adults aged 45-75. Mt-sDNA is indicated for asymptomatic individuals between the ages of 45 and 85, but not for those with rectal bleeding, iron deficiency anemia, adenomatous polyps, previous colonoscopy within 10 years, family history of CRC, positive results from CRC screening tests within the past 6 months, or age less than 45 and greater than 85. We aimed to determine the prevalence of mt-sDNA use when not indicated and factors associated with inappropriate testing. METHODS: 7,345 patients underwent mt-sDNA testing and were randomized using EMERSE. Charts for the first 500 patients were reviewed to determine whether mt-sDNA was ordered appropriately according to the USPSTF criteria. Seven patients were excluded due to having more than one inappropriate ordering for mt-sDNA. RESULTS: Of 500 patients, 22.2% had an inappropriately ordered mt-sDNA test. The most common reason for inappropriate ordering was having a previous colonoscopy done within the past 10 years. Rates of inappropriate testing significantly varied by race and the specialty of the ordering provider, with internal medicine providers ordering the most mt-sDNA tests. Rates of inappropriate testing did not significantly vary by sex or type of insurance. DISCUSSION: Our study suggests that providers may not be familiar with guidelines for the indicated use of mtsDNA, leading to inappropriate referrals and increased costs. Patients at increased CRC risk would benefit from a more sensitive procedure such as a colonoscopy. Future studies could understand the motivation to order testing outside approved indications through provider surveys and interviews.
引用
- Ahn AB, Kulhari S, Rhee J, et al. Inappropriate Ordering of Multitarget Stool DNA Tests for Colon Cancer Screening. J Am Board Fam Med. 2024. PMID: 38740492. doi:10.3122/jabfm.2023.230164R2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。